Abstract: Objective The aim of this study was to investigate clinical efficacy of antiviral therapy based on sorfosbuvir (SOF) combination in the treatment of patients with hepatitis C-induced liver cirrhosis (LC). Methods 39 patients with chronic hepatitis C-related compensated liver cirrhosis (CHC-CLC) and 23 patients with CHC-related decompensated liver cirrhosis (CHC-DLC) were encountered in our hospital between July 2019 and December 2022, and SOF and verapamil (VEL) combination was given in patients with CHC-CLC, and SOF and verapamil (VEL) combination plus ribavirin was given in patients with CHC-DLC for 12 weeks. Serum HCV RNA loads, biochemical index and routine blood cell counts were detected, and aspartate transaminase(AST)/platelet (PLT)ratio index (APRI) and fibrosis 4 score (FIB-4) were calculated. Liver stiffness measurement (LSM) was detected by Fibroscan. Results By end of treatment, two patients (8.7%) with CHC-DLC died; of survivals, early virologic response, end of treatment virologic response, sustained virologic response at 24 weeks (SVR 24) and SVR 48 in patients with CHC-CLC were 92.3%, 100.0%, 100.0% and 100.0%, all much superior to 80.9%, 100.0%, 76.2% and 66.7% (P<0.05) in patients with CHC-DLC; by end of antiviral treatment, peripheral blood platelet count and serum albumin level in patients with CHC-CLC were (140.6±26.3)×10⁹/L and (36.4±1.8)g/L, both significantly higher than [(70.5±27.0)×10⁹/L and (33.4±2.7)g/L, respectively, P<0.05] in patients with CHC-DLC; APRI, FIB-4 and LSM in patients with CHC-CLC were (1.1±0.4), (3.0±1.0) and (13.8±2.0)kPa, all significantly lower than [(1.7±0.7), (5.1±1.7) and (26.2±2.5)kPa, respectively, P<0.05] in patients with CHC-DLC. Conclusion DAAs therapy based on SOF has an satisfactory virological response in patients with CHC-CLC or CHC-DLC, with improved biochemical parameters, while the long-term efficacy needs further clinical observation.

Key words: Liver cirrhosis, Hepatitis C, Direct acting antivirals, Sophobovir, Liver fibrosis, Therapy